Medtronic Plc's Symplicity™ Spyral Procedure Shows Long-Term Efficacy in Hypertension Treatment
- Medtronic's Symplicity™ Spyral RDN procedure shows a significant 14.0 mmHg reduction in blood pressure over three years.
- The SPYRAL trial confirms long-term safety, with no significant renal artery stenosis reported in treated patients.
- Medtronic emphasizes the Symplicity system as a viable hypertension treatment, enhancing patient quality of life globally.
Medtronic’s Breakthrough in Hypertension Treatment: Long-Term Efficacy of Symplicity™ Spyral RDN Procedure
Medtronic plc, a leader in global healthcare technology, announces compelling long-term results from the SPYRAL HTN-ON MED randomized clinical trial, showcasing the effectiveness of its Symplicity™ Spyral renal denervation (RDN) procedure. The data, unveiled at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference, reveals substantial reductions in blood pressure among patients undergoing the Symplicity procedure over a three-year period. Specifically, the trial demonstrates that patients treated with RDN experience a 14.0 mmHg decrease in 24-hour ambulatory systolic blood pressure (ABPM), compared to a 9.3 mmHg reduction in the sham group, with a statistically significant difference (p=0.0028). Furthermore, office-based systolic blood pressure (OSBP) measurements show an 18.5 mmHg decrease in the RDN cohort, as opposed to an 11.7 mmHg reduction in the sham group (p=0.0002).
The SPYRAL trial also emphasizes the procedure's long-term safety profile, as no renal artery stenosis exceeding 70% was reported in patients receiving the RDN treatment. David Kandzari, M.D., co-principal investigator of the SPYRAL clinical program, highlights the durability of the blood pressure-lowering effects of the Symplicity procedure, reinforcing its potential as a reliable intervention for patients with uncontrolled hypertension. This is particularly significant given the chronic nature of hypertension and the challenges faced by many patients in managing their condition through medication and lifestyle changes alone.
With over 5,000 patients studied and more than 30,000 procedures conducted globally, the Symplicity blood pressure procedure establishes a benchmark in the field of renal denervation. Jason Weidman, senior vice president at Medtronic, emphasizes that the findings support the Symplicity system as a viable treatment option for those struggling with hypertension, underscoring its role in improving patient quality of life. As healthcare continues to evolve, Medtronic’s advancements in hypertension management provide hope for patients seeking effective long-term solutions.
In addition to the promising results from the SPYRAL trial, Medtronic’s commitment to innovation in cardiovascular care remains evident. The company’s focus on developing advanced technologies aligns with the growing need for effective treatments in the management of chronic diseases. As the healthcare landscape shifts towards patient-centered solutions, Medtronic is poised to lead with its cutting-edge therapies.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

